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Chapter One 
Introduction 
General features of Influenza viruses and infections:  
Nearly 700,000 people are hospitalized annually due to influenza virus infections 
in the United States alone, with outbreaks causing between 12,000 and 56,000 deaths 
every year (Maggie Fox, 2018).  These numbers do not always include those who die 
from other complications associated with the virus such as diabetes and cardiovascular 
disease.  The virus is spread in small droplets via cough, sneeze, or touch, which can 
infect individuals (Influenza (Flu), 2018).  First or second hand contraction can occur by 
someone sneezing, causing the droplets to enter your mouth/nose (Influenza (Flu), 
2018).  Additionally, the virus can exist on contaminated surfaces therefore leading to 
possible infection if touched.  Once the virus enters your body, immediate action must 
be taken by your immune system to defend its host.  The immune system responds by 
sending white blood cells, such as T cells and other inflammatory molecules such as 
cytokines, to attack the virus (Jabr, 2017).  The main part of the body where the virus 
resides is in the lungs/respiratory tract.  If the immune system responds properly, the 
virus should be cleared from the host and recovery takes approximately one week.  If 
the immune system responds too aggressively, the inflammatory molecules produced 
can destroy too much lung tissue, causing the lungs to be incapable of delivering the 
proper amount of oxygen to the blood, leading to death (Jabr, 2017).  Other secondary 
complications such as bacterial pneumonia, encephalitis, and myocarditis are very 
dangerous as well.  This is why the development of a universal flu shot is critical, with its 
ability to save millions of lives.     
 4 
 The CDC categorized influenza into five different categories: seasonal, avian, 
swine, variant, and pandemic (Influenza (Flu), 2018).  It is also broken down into 4 
different virus types: A, B, C and D.  Due to the different categories and viruses 
circulating at any given time, the vaccine is constantly changing each year.  Scientists 
and researchers review and study the vaccine composition annually hoping to protect 
as many people as possible.  The CDC, the FDA, physicians, pharmacists, and nearly 
all other experts agree that the most effective way to combat this disease is through the 
influenza vaccine.  In Dr. Huber’s laboratory I was able to test the ability of a universal 
influenza vaccine candidate to induce antibodies against both human and swine viruses 
using hemagglutination inhibition assays.  
Vaccine-induced immunity against influenza viruses: 
Hemagglutination inhibition assays (HAI assays) are used to detect and quantify 
the concentration of antibody in serum and rely on the natural ability of influenza viruses 
to bind red blood cells through a process known as hemagglutination.  The HAI assay is 
the gold standard for antibody detection against these viruses.  HAI assays are used to 
show if an influenza virus causes hemagglutination in blood, or if antibodies present in a 
sample can inhibit hemagglutination.  Influenza viruses are composed of a glycoprotein 
envelope that can bind to sialic acid molecules found on the sialic acid residues that 
serve as receptor sites on red blood cells (Racaniello, 2009).  Usually when red blood 
cells are put into a saline solution the cells will gradually drop to the bottom of a tube 
due to gravitational forces, appearing as a red dot.  However, when viruses are added 
to the solution, interactions between the virus and red blood cells may be seen.  The red 
blood cells are prevented from falling to the bottom on the tube and instead a shield is 
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formed keeping the cells suspended (Racaniello, 2009). This can be seen as a foggy 
red liquid rather than a single red dot (Figure 1).  If a patient's serum contains 
antibodies that block viral attachment to red blood cells, this interaction is inhibited, and 
the red blood cells will settle to the bottom of the tube in a manner that looks like virus is 
not present.  Influenza viruses are highly specific to the antibodies used within HAI, 
making the use of this method highly effective for antibody detection.  The assay can be 
easily modified to determine the level of antibodies against influenza virus that are 
present in serum samples, with pig and mouse serum being among some of the most 
popular sera samples to test for antibodies after vaccination.  In this study, I used the 
HAI assay to test specific influenza viruses against sera taken from animals that were 
vaccinated with an H1N1 universal vaccine candidate.   
Every influenza season is different, with variants of the influenza A and B types, 
notably represented by the influenza A subtypes H1N1 and H3N2, circulating every 
season.  This makes matching the vaccine with the circulating variant nearly impossible.  
The traditional trivalent vaccine (annual vaccine) protects against H1N1 (Influenza A), 
H3N2 (Influenza A), and influenza B virus, while the quadrivalent vaccine includes an 
additional influenza B virus (CDC, 2018).  In 2009 we saw a novel variant of the H1N1 
virus spread around humans causing a global pandemic.  This virus contained swine, 
human, and avian genetic components, and was vastly different from the variants that 
circled during the past 30 years.  This meant that the novel virus and the vaccine did not 
match, leading to more incidences of influenza, which coincided with increases in 
hospitalization rates and deaths.  Since the immune system of children are naïve, and 
the immune systems of elderly are weak, both populations are more vulnerable to 
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severe influenza virus infections and are at a higher susceptibility to death (Jabr, 2017).  
However, despite these hospitalization rates, in 2009, young adults were the group that 
was most affected by this novel H1N1 virus that replaced the seasonal H1N1 variant 
that was previously circulating (Jabr, 2017).   A seasonal vaccine against this novel 
variant still remains the gold standard of protection against influenza.  Since matching 
each variant on an annual basis is also very time consuming (Gerdil C., 2003), broad 
immunity may be a possibility in the future.  However, the annual changes that occur as 
influenza escapes host immunity makes induction of broad immunity very difficult.  In 
order to increase the breadth of immunity induced, a DNA shuffling strategy was 
proposed as a potential solution.  
Can we create a vaccine that induced immunity against multiple H1N1 variants?: 
DNA shuffling is a process of randomly recombining parental genes to create a 
novel gene that expresses a protein containing desired properties of the individual 
parental genes (Joern, J. M., n.d.).  In our case, DNA shuffling is being used to create a 
single protein that can induce immunity against 4-5 parental influenza A H1N1 variants.  
This is very important for influenza viruses because they can cross a species barrier, 
which was the case in 2009.  The novel H1N1 variant, also known as the swine flu, had 
the ability to move freely between pigs and humans (Berlanda Scorza, F., et al., 2016). 
The method used in the Huber lab induces immunity against the HA protein using 
epitopes, which are the part of an antigen molecule to which an antibody attaches itself.  
This method is intended to both prevent transmission between pigs and humans, and 
stop virus spread among pigs and among humans.  The approach could be utilized to 
create a pre-pandemic vaccine that would also be useful during the early stages of a 
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pandemic.  If we can prevent the virus from circulating within the swine population, this 
may ultimately mean a decrease in transmission from pigs to humans as well.    
Previous work in the Huber lab showed that recombined chimeric genes created 
by DNA shuffling can attain the properties described above.  Specifically, a single 
protein had the ability to induce antibodies against 4-5 parental variants (McCormick, et 
al., 2015).  These “desired genes” specifically contain influenza A virus hemagglutinin 
(HA) sequences and the ability to induce antibodies was evaluated in both mouse and 
pig models (McCormick, K., et al. 2015).  Molecular breeding can speed up the 
evolution of a virus (Crameri A, Raillard, 1998), and this was the method used to create 
the previous vaccine against influenza A in pigs.  One restriction of the vaccine 
produced was that only one of the HA’s could be expressed within a conventional 
vaccine, and this HA was known as HA-129.  However, screens that were done using 
DNA vaccines for all of the chimeric HAs produced showed that one additional gene-
shuffled products, HA-113, could induce immunity with increased breadth and strength, 
compared to HA-129.  Although we were unable to express HA-113 using conventional 
vaccine methods that were available in the Huber lab, we were able to utilize the 
parainfluenza virus 5 (PIV-5) technology that was available through collaboration with 
Biao He (University of Georgia, Athens, GA).  PIV-5 was used as a vector for delivery of 
influenza hemagglutinins created using DNA shuffling as universal vaccine candidates 
(Figure 2), specifically the HA-111 and HA-113 genes.  
Parainfluenza virus-5 (PIV-5) as a vaccine vector: 
Many viruses can enter though the respiratory tract. This includes the influenza 
virus, paramyxoviruses, coronaviruses, pox viruses and herpes viruses (Clark, K. M., et 
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al. 2011).  Paramyxoviruses can infect the respiratory tract and cause a wide variety of 
human and animal diseases (Welch BD, et al., 2013).  We have chosen PIV5 as a 
vector for vaccine delivery based on a number of characteristics of this paramyxovirus.  
First, the vaccine has been demonstrated as safe as it was tested in a live vaccine 
against kennel cough in dogs.  No adverse events were reported.  Additionally, PIV5-
based vaccines will not interfere with prior immunity against PIV5 (Chen Z., 2012 ).  
Lastly, PIV5 vectors can induce immunity against different influenza A virus subtypes in 
mice, thus PIV-5 is a viral vector that is a promising candidate for vaccine development 
(Li Z., et al., 2013).  With this information, PIV5 was utilized as our vector for influenza 
HAs, and here we report on the testing of a PIV5 expressing HA-113 (PIV5-113) in both 
mice and pigs.  This PIV5-113 vaccine induced broad immunity in both animal models, 
with quantifiable readouts being detection of antibodies and the ability to protect against 
virus infection.  The findings are presented below and discussed in the context of how 
broad vaccine-induced immune responses can prevent both seasonal and, potentially, 
pandemic influenza virus infections. 
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Chapter Two 
Methods and Materials 
Parental HA Genes 
The HA genes of parental H1N1 influenza A viruses, including A/Tennessee/1-
560/09 (TN09), A/NewJersey/8/1976 (NJ76), A/Ohio/01/2007 (OH07), and 
A/Iowa/01/2006 (IA06) were isolated from stock viruses and cloned as described 
(McCormick, et al., 2015).  Additional H1N1 influenza A virus strains, were used to test 
antibodies induced for cross reactivity, as described below.  Viruses expressing TN09, 
NJ76, OH07, and IA06 HA proteins were used to determine the reactivity of HA-113-
induced antibodies against the parental viruses.  The primary viruses expressing HA 
proteins from the A/Germany/81, A/Iowa/92, A/Brisbane/07, A/California/09, 
A/Michigan/15, and A/swine/Iowa/13E100/2013 were used to test the breadth of 
immunity induced by the vaccine candidate.  A/Brisbane/59/2007 HA is antigenically 
similar to the A/Memphis/3/2008 HA, and both of these viruses circulated in humans 
immediately prior to the H1N1 pandemic in 2009.  Additionally, the A/Michigan/2015 
virus represents the H1N1 variant that was included in the 2017 human vaccine, 
replacing the A/California/4/2009 isolate that had been in the vaccine since 2009.  The 
A/swine/Iowa/13E100/2013 virus was isolated from a nasal swab taken from a healthy 
pig in Iowa in May of 2013.  The A/Michigan/2015 virus and the 
A/swine/Iowa/13E100/2013 virus are particularly crucial in the evaluation of our PIV5-
113 vaccine because these viruses were both isolated after the 2009 pandemic.  Since 
2009 was the last year for inclusion of a parental HA in the vaccine, these viruses are 
being used to determine whether the vaccine can induce immunity against future human 
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(Michigan) and swine (13E100) viruses that circulated in their populations after the 
vaccine had been created by DNA shuffling.  
Creation of PIV-113 
Using sequences from previously shuffled genes (McCormick, et al., 2015). Biao 
He created PIV5 vaccine expressing HA-113 (PIV5-113).  This was done by expressing 
the DNA sequence from the shuffled HA gene HA-113 (McCormick, et al., 2015) in PIV5 
(ZL48 virus) between the genes expressing hemagglutinin-neuraminidase (HN) and the 
large RNA polymerase (L) proteins (Mooney AJ., 2013). 
Vaccination using PIV5-113    
Using PIV5 expressing HA-113 (PIV5-113) as a vaccine, post-vaccination sera 
samples were taken on days 7, 14, 21, and 28 and tests were performed to monitor 
antibody production.  Mice were immunized with PIV5-113 and then given a booster on 
day 28 and sera were collected three weeks later.  Pigs were immunized with PIV5-113 
and given a booster 14 days later.  After vaccination, pigs and mice were challenged 
with influenza viruses and nasal swabs were taken on day 1 post challenge, day 3 post 
challenge, and day 5 post challenge.  Tests including the HAI assay, as described 
below, were performed.  Focusing on HAI assays, the sera samples provided sufficient 
data to show antibody production against parental influenza strains.  In this study we 
evaluated vaccine-induced immunity using PIV5 expressing HA-113 (PIV5-113) using 
both mouse and pig models of vaccine:challenge.  As a control, the vector alone (PIV5 
alone) was delivered to both mice and pigs.   
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Hemagglutination Inhibition Assay (HAI) 
Hemagglutination inhibition (HAI) assays were performed to evaluate antibody 
levels in the sera collected (Figure 1).  The highest dilution of serum that prevents 
hemagglutination is called the HAI titer for that serum sample (Acharya, 2018).  To 
perform the HAI assay the virus is diluted across a 96-well, round-bottom plate (50μl 
PBS to columns 2-13, 100μl virus in the 1st column).  A solution of 0.5% red blood cells 
in 50 microliters is then added to each well to determine the amount of virus present.  
After 30 minutes, hemagglutination can be observed.  The virus stock is diluted to a 1:8 
titer in 50 microliters and tested to confirm a titer of 1:8 using the dilution system 
described above.  Once the virus stock is at a 1:8, it can be used in the HAI assay to 
determine whether the antibody present in the serum can inhibit virus interactions with 
red blood cells.  
For the HAI assay, a round-bottom 96-well plate is used, and 25 microliters of 
PBS is added to each well with the exception of the first well in a row or column 
(depending on the dilution scheme).  Mouse and pig sera that are used in the HAI assay 
are initially treated with RDE, heat inactivated, and pre-cleared with red blood cells to 
remove natural inhibitors to the assay, as described (McCormick, et al., 2015).  After 
treatment, serum samples are added to the first well in a 50 microliter volume and 
diluted as described above for virus, using 25 microliters as the transfer volume 
between wells.  After the sera have been diluted, 25 microliters of virus (4 
hemagglutinating units, based on the 1:8 titer in 50 microliters that was determined 
previously) is added to each well.  Plates containing diluted antibody and virus are 
incubated for an hour before adding 50 microliters of 0.5% red blood cells.  After 30 
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minutes the HAI titer can be observed and recorded.  Since antibodies against influenza 
HA have the ability to prevent attachment of the virus to the red blood cells, the highest 
dilution of serum that prevents hemagglutination (hemagglutination inhibition) is called 
the HAI titer of the serum (Racaniello, 2009).  Titers are reported as the reciprocal of the 
final serum dilution that inhibits hemagglutination.  A titer 5 is assigned to serum 
samples that did not demonstrate HAI at the starting dilution of 1:10.  HAI assays were 
performed on both mouse and pig serum.   
Mouse Challenge 
 Mice were immunized with PBS, PIV5, or PIV-113.  They were given a second 
dose of their respective vaccine 28 days later as a boost, and sera were collected 20 
days after this second inoculation.  Mice were challenged with mouse-adapted viruses 
expressing the parental HA’s from A/Tennessee/1-560/09 (TN09), A/NewJersey/8/1976 
(NJ76), A/Ohio/01/2007 (OH07), and A/Iowa/01/2006 (IA06), and A/Memphis/3/2008 
(ME08).  These viruses were created as described previously (McCormick, et al., 2015), 
and mouse challenge studies were performed as described (Huber, 2009). 
Pig Challenge 
Pigs were immunized with PBS, PIV5, or PIV-113 and boosted with their 
respective vaccines on day 14.  Sera were collected 14 days later and challenged with 
the viruses.  Nasal swabs were taken on day 1 post challenge, day 3 post challenge, 
and day 5 post challenge.  These viruses were created as described previously 
(McCormick, et al., 2015). 
Ethics Statement 
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 All work performed with influenza viruses was done in accordance with protocols 
that were approved by the Institutional Biosafety Committee of the Unviersity of South 
Dakota (USD) and Kansas State University (KSU).  Work in mice was done following 
experimental conditions approved by the Institutional Animal Care and Use Committee 
(IACUC) of USD, while work in pigs followed IACUC-approved procedures established 
at KSU. 
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Chapter Three 
Results 
 
In this study, both mice and pigs were vaccinated with a Parainfluenza Virus 
(PIV-5) vector that expressed HA-113 (PIV5-113, Figure 2).  I will first discuss the 
results found with the challenge in mice, which was work that was completed by Sarah 
Zaiser before I joined the Huber lab, and then I will discuss the results for the vaccine 
and challenge of pigs, which was done by Ying Fang at Kansas State University 
(Manhattan, KS).  My specific role in this study was to use the HAI method to test and 
determine the antibodies induced after vaccination in both mice and pigs.  The complete 
results are being presented as a way to relay the contribution of my work in the big 
picture of the project. 
Mice vaccinated with PIV5-113 demonstrated immunity against individual 
influenza viruses that expressed HA proteins from all 5 parental viruses (Figure 3).  All 
of the PIV5-113 vaccinated mice that were challenged with NJ76-, IA06-, OH07-, and 
TN09-expressing, mouse-adapted viruses showed protection against the lethal 
challenge, while none of the mice challenged with the ME08-expressing virus survived 
(Figure 4).  This means that although antibodies were induced against ME08 by the 
PIV5-113 vaccine, the levels were not high enough to provide protective immunity.  The 
gold standard for protective immunity against influenza infection is an HAI titer of 40, 
which is a titer that is defined for population studies.  It is known that 50% of people that 
have a titer of 40 will be protected from virus infection, but individuals may vary in the 
relationship between antibody titer and protection against infection.  ME08 had an 
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average titer of approximately 20, which was not strong enough to provide protection 
against this virus. 
Since immunity was achieved in the mice using the novel PIV5-113 vaccine, a 
vaccine:challenge study was performed in pigs.  Pigs are a more closely related species 
to humans and pandemics arise from swine, making them a vital tool in vaccine 
research and an important population to test our vaccine.  In fact, the PIV5-113 vaccine 
has the ability to be mass-produced and used directly in pigs, if it can demonstrate 
value in pilot studies like this.  Pig serum samples from PIV5-113-vaccinated animals 
were tested for their reactivity against viruses expressing NJ76, IA06, OH07, TN09 and 
ME08 HA proteins.  Results show an antibody response against all viruses except 
ME08 once again (Figures 5 and 6), which is not surprising since immunity against this 
virus did not reach a titer of 40 in mice either.  Similar to the results in mice, we would 
predict that challenge of pigs with viruses expressing NJ76, IA06, OH07, and TN09 
would be protective.  Meanwhile, a challenge with a virus expressing ME08 would not 
show protection since it had a titer of approximately 20.  These results show that our 
PIV5-113 vaccine could induce immunity in pigs similarly to what was observed in mice.   
To determine whether PIV5-113 could induce broad immunity in pigs, we 
performed HAI assays using non-parental viruses expressing HA proteins from the 
IA92, CA09, MI15, GE81, BR07, and 13E100 viruses (Figure 7).  These viruses are 
from the H1N1 family, and many were used in our previous study to demonstrate the 
breadth of immunity induced in pigs with the HA-129 vaccine (McCormick, et al., 2015).  
These were chosen because they are viruses that circulate in both pigs and humans, 
including viruses that circulated after our vaccine was created.  The results show that 
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viruses expressing the BR07 and GE81 HAs had HAI titers that were less than 40, 
similar to the ME08 virus.  Once again this would predict an inability for our vaccine to 
protect against direct challenge with these viruses.  However, HAI titers against CA09, 
which was the H1N1 isolate included in vaccines starting in 2009 and is closely related 
to TN09, were similar to those detected against NJ76, IA06, OH07, and TN09, 
predicting protection.  Interestingly, the MI15 and 13E100 viruses that represent viruses 
circulating in humans in 2015 and pigs in 2013 reacted with antibodies induced by PIV5-
113 vaccines, showing that the PIV5-113 vaccine could provide immunity against 
influenza viruses that circulated in pigs and humans after its creation in 2009.  This 
shows an added value of our vaccine.  It indicates that with updates, a higher titer may 
be able to be achieved against all of these viruses.  Since both Cal09 and MI15 had 
titers over 40, the PIV5-113 vaccine has potential as a candidate vaccine for current 
and future vaccines.  In the future we will continue to test viruses post 2009 pandemic to 
provide more information related to virus evolution away from the breadth of protection 
provided by PIV-113.   
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Legend 
 
 
Figure 1: This figure shows hemagglutination versus hemagglutination inhibition 
as described in the methods and materials section (Acharya, 2014). Since antibodies 
against influenza HA have the ability to prevent attachment of the virus to the red blood 
cells, the highest dilution of serum that prevents hemagglutination (hemagglutination 
inhibition) is called the HAI titer of the serum (Racaniello, 2009).   
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Figure 2: This figure shows how an HA expressing virus (novel HA) was created, 
PIV5-113.  Biao He created PIV5 vaccine expressing HA-113 (PIV5-113) using 
previously shuffled genes.  PIV5 was utilized as a vector as described in method and 
materials.  Picture provided by Biao He.   
 
 
 
 
 
 
 
 
 
 
 
 19 
 
 
 
Figure 3: The data above shows the reactivity of sera from pigs vaccinated with 
HA-113.  Reactivity against parental HAs is shown.  The number of mice per vaccine 
group were as follows: 20 mice for PBS, 40 mice for PIV5, and 39 mice for PIV5-113. 
Data provided by Sarah Zaiser. 
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Figure 4: This graph shows the influenza vaccine:challenge study in mice. Protective 
immunity established.  The numbers of mice per challenge were as follows: 4 per 
challenge for PBS, 8 per challenge for PIV5, and 7-8 per challenge for PIV5-113.  Data 
provided by Sarah Zaiser. 
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Figure 5:  This graph shows the influenza vaccine:challenge study in mice. Protective 
immunity established.  The numbers of mice per challenge were as follows: 4 per 
challenge for PBS, 8 per challenge for PIV5, and 7-8 per challenge for PIV5-113.  Data 
provided by Sarah Zaiser. 
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Figure 6:  HAI assay results after vaccination in pigs.  There were 6 pigs per vaccine 
group.  ME08 showed no antibody detection, but NJ79, IA06, OH07 and TN07 all had 
antibody detection after vaccine delivery.   
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Figure 7: HAI assay results after vaccination in pigs.  There were 6 pig per vaccine 
group. IA92, CA09 and MI15 all had antibody detection after vaccine delivery, but BR07 
and GE81 did not.   
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Chapter Five 
 
Discussion and Summary 
 
Currently influenza prevention depends on predicting which variants of the virus 
will circulate throughout the year and then creating vaccines that protect against those 
variants. The World Health Organization is responsible for selecting three strains that 
will resemble the ones circulating during influenza season in the Northern and Southern 
hemispheres (CDC, 2018).  Pandemics (antigenic shift) and epidemics (antigenic drift) 
can be misinterpreted, and we have been poorly prepared for these situations when 
they arise.  Our PIV5-113 vaccine provides sufficient data to give hope to the possibility 
of a universal influenza vaccine.  This single vaccine induced immunity against 
influenza viruses that circulated in pigs and humans both before and after the novel 
H1N1 virus that caused a pandemic in 2009.  With its creation, and successive 
improvements in both design and immunogenicity, pandemic and epidemic influenza 
infections can be prevented.  
Pandemics represent a more rapid and dramatic change in the genetic makeup 
of viruses through re-assortment of the individual virus genes, and they usually come 
from a known source, such as another species like pigs or birds.  When influenza 
viruses cross from animals to humans, novel or “pandemic” stains are be generated 
(Berlanda Scorza, F., et al., 2016).  According to the CDC, “An influenza pandemic is a 
global outbreak of a new influenza A virus.  Pandemics happen when new (novel) 
influenza A viruses emerge which are able to infect people easily and spread from 
person to person in an efficient and sustained way” (Pandemic Influenza, n.d.).  
Alternatively, epidemics arise through an accumulation of point mutations that arise as 
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the virus evolves to escape adaptive immunity and they lead to annual vaccine 
changes.   
In cases like the 2009 H1N1 influenza pandemic, a vaccine might need to be 
created after the strains for the season have already been selected (Huber VC, et al., 
2009).  Based on the statistics for deaths and hospitalization provided by the CDC, the 
method currently used is clearly not very efficient, especially during the initial wave of a 
pandemic.  Viruses in birds and pigs can be studied before they emerge in humans.  If 
this knowledge is available, a pre pandemic vaccine can be created.  Using PIV5 and 
creating an HA like HA-113, which was created using DNA shuffling, broad immune 
responses can be induced.  Four phylogenetic clades were represented by the chosen 
parental influenza A H1N1 strains, covering those known to circulate in pigs.  HA genes 
of these parental strains (NJ76, IA06, OH07, ME08, and TN09) were used for DNA 
shuffling and here we evaluated the HA-113 chimeric construct created.  PIV5 was 
utilized as a vector for expression of this candidate chimeric HA protein.  The data 
presented here show that HA-113 expressed in PIV5 can induce immunity against HA 
proteins representing parental HAs that are included within the DNA-shuffled sequence 
and that the PIV5-113 vaccine induced antibody titers at levels that protected against 
NJ76, IA06, OH07, and TN09 virus infections.  Antibodies were also induced against 
ME08 when the PIV5-113 vaccine was used, but these did not protect against challenge 
with an ME08-expressing virus.  It is worth noting that this virus circulated in humans 
prior to 2009 and was much different than the other viruses used in DNA shuffling.   
It may be possible to create a universal vaccine using DNA shuffling, which 
creates recombined chimeric HA proteins.  By incorporating HA epitopes from swine 
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and human influenza viruses into the vaccine, this could be utilized as a pre pandemic 
vaccine to decrease the amount of people infected with this virus.  The HA epitopes 
should allow the vaccine-induced antibodies to recognize the circulating virus and allow 
for the recognition of viruses that evolve later.  The prime example of this is how PIV5-
113 induced antibodies against a virus isolated from pigs in 2013 (13E100) and the 
human virus from 2015 (MI15).  This indicated that the immunity against the evolved 
HAs is maintained by the chimeric HA vaccine.  By creating a vaccine that can prevent 
the virus from circulating around the swine species, this could lessen the chances of a 
pandemic like the one that occurred in 2009.   
According to the CDC, “Improved surveillance of influenza in pigs and other 
animals may help to detect the emergence of influenza viruses with the potential to 
cause illness and spread among people, possibly resulting in a pandemic.  Early 
detection of such viruses can alert public health officials and aid in pandemic 
preparedness through the development of appropriate diagnostic tests and influenza 
vaccine candidate viruses, if necessary” (Origin of 2009 H1N1).  By using DNA 
shuffling, we were able to create a vaccine that induced enough antibodies to provoke 
an immune response. 
 Creating chimeric HA’s of the H1N1 subtype via DNA shuffling is a much more 
proactive solution than the current method.  Since the HA construct showed 
immunogenicity in both mice and pigs, it is hypothesized that it could induce protective 
immunity amongst the circulating variants in humans.  The MI15 virus, which is a virus 
from 2015 that was isolated after the 2009 epidemic, was recognized by antibodies 
induced by PIV5-113.  This indicates that other viruses from after 2009 should be tested 
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to see where and when the degree of PIV5-113 reactivity ends.  If a vaccine is 
developed using this approach, pandemics will hopefully be avoided, and vaccines 
could target both pigs and humans to limit interspecies transmissions that are 
associated with pandemics.  In the DNA-shuffling approach a new chimeric HA can be 
created and tested when the PIV5-113 no longer induces sufficient antibodies.   
In summary, the current method of developing vaccines is too slow to prevent 
pandemics (Robertson JS, et al., 2011), but the PIV5-113 vaccine tested here showed 
antibody responses in mice pigs that predict similar performance in humans.  This 
means that a vaccine like PIV5-113 may limit transmission events between pigs and 
humans, which would be important either before a pandemic or early during the 
pandemic.  If this would have been available in 2009, the pandemic could have been 
lessened or avoided completely.  Hopefully my work in Dr. Huber’s laboratory 
contributes to the possibility of developing a universal vaccine with broad immunity.  
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